BB Biotech AG (XSWX:BION) Change In Receivables: CHF0.0 Mil (TTM As of Mar. 2026)


XSWX:BION BB Biotech AG XSWX:BION
34 GF Score
Price CHF50.60
! 4 Warning Signs
View Full Analysis

What is BB Biotech AG Change In Receivables?

BB Biotech AG XSWX:BION -1.75% 34 Change In Receivables is CHF0.0 Mil as of Mar. 2026. GuruFocus rates XSWX:BION with a GF Score™ of 34/100. The stock has 4 warning signs investors should review.

BB Biotech AG's change in receivables for the quarter that ended in Mar. 2026 was CHF0.0 Mil. It means BB Biotech AG's Accounts Receivable stayed the same from Dec. 2025 to Mar. 2026 .

BB Biotech AG's change in receivables for the fiscal year that ended in Dec. 2025 was CHF0.0 Mil. It means BB Biotech AG's Accounts Receivable stayed the same from Dec. 2024 to Dec. 2025 .

BB Biotech AG's Accounts Receivable for the quarter that ended in Mar. 2026 was CHF0.0 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. BB Biotech AG's liquidation value for the three months ended in Mar. 2026 was CHF347.1 Mil.

BB Biotech AG  (XSWX:BION) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

BB Biotech AG's Days Sales Outstanding for the quarter that ended in Mar. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/-17.039*91
=

2. In Ben Graham's calculation of liquidation value, BB Biotech AG's accounts receivable are only considered to be worth 75% of book value:

BB Biotech AG's liquidation value for the quarter that ended in Mar. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=354.971-7.86+0.75 * 0+0.5 * 0
=347.1

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BB Biotech AG Change In Receivables Related Terms

BB Biotech AG Change In Receivables Historical Data

* Premium members only.

The historical data trend for BB Biotech AG's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BB Biotech AG Change In Receivables Chart

BB Biotech AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BB Biotech AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XSWX:BION
34GF Score
BB Biotech AG XSWX:BION
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BB Biotech AG Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of CHF0.0 Mil mean?
BB Biotech AG (XSWX:BION) has a Change In Receivables of CHF0.0 Mil as of Mar. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for BB Biotech AG and its competitors.
Is BB Biotech AG's Change In Receivables too high?
BB Biotech AG's current Change In Receivables is CHF0.0 Mil. Overall, BB Biotech AG has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does BB Biotech AG's Change In Receivables compare to VRTX and REGN?
BB Biotech AG's Change In Receivables of CHF0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for BB Biotech AG and its competitors. BB Biotech AG's current Change In Receivables is CHF0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BB Biotech AG stock overvalued right now?
BB Biotech AG (XSWX:BION) has a current Change In Receivables of CHF0.0 Mil. The current Change In Receivables is CHF0.0 Mil. BB Biotech AG's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For BB Biotech AG (XSWX:BION), the current Change In Receivables is CHF0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BB Biotech AG Business Description

Address Schwertstrasse 6, Schaffhausen, CHE, CH-8200
BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market, and is one of the investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. Geographically company operates in the USA, Netherlands, Singapore, Great Britain, Canada, Switzerland, Curacao, and British Virgin Island.
34GF Score

Get the complete analysis for XSWX:BION

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF50.60
Price